INTRODUCTION The timing of tumor specific palliative therapy and its influence on the survival of patients with stage IV lung cancer remains unclear. METHODS 375 patients with stage IV lung… Click to show full abstract
INTRODUCTION The timing of tumor specific palliative therapy and its influence on the survival of patients with stage IV lung cancer remains unclear. METHODS 375 patients with stage IV lung cancer who experienced an early or delayed therapy (early or delayed therapy group; TG) were investigated using histology and ECOG performance score-related (ECOG-PS) subgroups. Kaplan-Meier and Cox regression analyses were used for survival analyses. RESULTS Patients in the early TG had a significantly shorter median overall survival (OS) than those in the delayed TG (6 vs. 11 months). Patients with an ECOG-PS of ≥1 were significantly more present in the early than in the delayed TG (66.8% vs. 51.9%). But an early therapy was also significantly associated to a shorter median OS in ECOG-matched subgroups (ECOG-PS of 0; 7 vs. 23 months, ECOG >1 ; 6 vs. 8 months). An early therapy was associated to a significantly worse median OS in histological subgroups (NSCLC; 5 vs. 11 months, SCLC; 7 vs. 11 months) and was an independent risk factor in uni- and multivariate analyses. CONCLUSIONS An early initiation of cancer specific therapy was associated with a shorter survival time in palliative lung cancer patients, independent of the ECOG-PS and histological subtype.
               
Click one of the above tabs to view related content.